Fang, Shen-Cun <br/><br/>
Apatinib as post second-line therapy in EGFR wild-type and ALK-negative advanced lung adenocarcinoma.  [electronic resource] 

 -  OncoTargets and therapy  2017 
 - 447-452 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1178-6930 
<br/><br/><label>Standard No.: </label>10.2147/OTT.S126613  doi